ResearchSafe

Minoxidil (Minoxidil (Rogaine))

Category: Hair Growth. Status: FDA Approved (OTC).

A potassium channel opener and vasodilator that stimulates hair growth independent of hormonal mechanisms. Works for both men and women with androgenetic alopecia. Available OTC in topical and increasingly used oral (low-dose).

How it works

Opens ATP-sensitive potassium channels in vascular smooth muscle and hair follicle cells. Increases blood flow and nutrient delivery to follicles. Prolongs anagen (growth) phase and stimulates VEGF expression for neovascularization around follicles.

Key facts

  • Molecular weight: 209.25 Da
  • Half-life: ~4 hours (systemic); active in follicle for 22h
  • Bioavailability: ~95% oral; topical: local depot effect
  • Storage: Room temperature. Topical: keep away from heat/flame.

Dosing overview

  • Typical dose: 5% topical (1mL 2x/day) or 2.5-5 mg oral
  • Frequency: Twice daily (topical) or once daily (oral)
  • Duration: Ongoing (lifelong for maintenance)
  • Route: Topical solution/foam or oral tablet

Reported benefits

  • Stimulates new hair growth
  • Works independently of DHT pathway
  • OTC availability
  • Effective for both sexes
  • Prolongs anagen phase
  • Can combine with any other treatment

Possible side effects

  • Initial shedding (temporary)
  • Scalp irritation (topical)
  • Unwanted facial hair (women)
  • Low blood pressure/dizziness (oral)
  • Fluid retention (oral)
  • Heart palpitations (rare, oral)

Research

  • Oral minoxidil vs topical for AGA (2022): Oral minoxidil 5mg/day produced equivalent or superior hair counts to topical 5% with better compliance but more systemic side effects.
  • Low-dose oral minoxidil safety (2023): 2.5mg/day showed significant hair density improvement with minimal cardiovascular effects (no clinically significant BP changes) over 24 weeks.

Compare Minoxidil

Community discussions about Minoxidil

Research and educational reference only. Not medical advice.